Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 393

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 393
---
 selected events may differ materially from those anticipated in these forward -looking statements as a result of various factors, including those set forth under “Risk Factors” or elsewhere in this proxy statement / prospectus. Overview Prior to the Heritas Contribution (as defined below), we have substantially conducted our business operations through Heritas Argentina. Heritas Argentina was incorporated on July 10, 2015 and is registered with the public registry of Rosario, circunscripciónN°1, Santa Fe, Argentina, under the number T98 F252 N12. It initially focused on developing proprietary clinical tests in genomics and reproductive health. Leveraging Bioceres’ scientific team and CIBIC’s extensive experience in clinical diagnostics, Heritas Argentina successfully launched precision medicine products and services, and it specializes in clinical genetic services, offering tests that cater to diverse medical fields such as oncology, prenatal care, and rare diseases. In response to changing consumer habits which resulted from the COVID -19pandemic, Heritas Argentina expanded its offerings by launching Rewell, a direct -to -consumerbrand focused on at -homeDNA and microbiome testing. Rewell aims to empower consumers through personalized health data to enhance their long -termwell -beingthrough optimal lifestyle choices. In addition, Rewell’s services include a secure digital platform for accessing test results and scheduling, in certain circumstances, consultations, complemented by tailored health plans aimed at prevention and wellness. Pursuant to a contribution agreement between the Parent and us, on February 26, 2024, all of the issued and outstanding shares of Heritas Argentina were contributed to us, resulting in Heritas Argentina becoming our wholly owned subsidiary (the “Heritas Contribution”). In exchange for the Heritas Contribution, we issued 30 million shares to the Parent. This restructuring was completed with a view to prepare us for our strategic business combination with APx. Key Factors Affecting Operating Results The Company has historically incurred significant losses: $4,516,095 and $1,291,932 for the fiscal years ended June 30, 2024 and 2023, respectively. The Company has also recorded accumulated deficits of $6,941,483 and $3,588,427 as of June 30, 2024 and 2023, respectively. Additionally, the Company recurring cash outflows from operations amounted to $1,885,895 and $1,306,705 for the years ended June 30, 2024 and 2023. We expect to continue to